<DOC>
	<DOCNO>NCT01352728</DOCNO>
	<brief_summary>The survival subject unresectable hepatocellular carcinoma ( HCC ) receive transarterial chemoembolization improve addition axitinib .</brief_summary>
	<brief_title>Hepatocellular Carcinoma ( HCC ) Transarterial Chemoembolisation ( TACE ) +Axitinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>1 . Histologically confirm HCC ( fulfil AASLD criterion HCC diagnosis HBsAg positive subject cirrhosis case biopsy feasible ) 2 . Disease must amenable potentially curative surgery 3 . Without prior systemic transarterial treatment 4 . Prior surgery local therapy allow target lesion must previously treat 5 . ChildPugh stage A liver function 6 . ECOG performance 02 7 . Life expectancy longer 12 week 8 . At least one measurable treatment lesion accord modify RECIST criterion 9 . Adequate haematological , hepatic renal function 1 . Contraindications TACE treatment : Main portal vein thrombosis occlusion Evidence biliary obstruction Presence extrahepatic disease 2 . Diffusetype HCC 3 . Major surgery &lt; 4 week radiation therapy &lt; 2 week start study treatment . 4 . Any form prior transarterial therapy systemic therapy HCC . 5 . Current use anticipate need treatment drug know potent CYP3A4 inhibitor CYP3A4 CYP1A2 inducer . 6 . Requirement anticoagulant therapy oral vitamin K antagonist . Low dose anticoagulant maintenance patency central venous access devise prevention deep venous thrombosis allow . Therapeutic use low molecular weight heparin allow . 7 . Any haemorrhage bleeding event CTCAE Grade 3 within 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Unresectable</keyword>
</DOC>